Trials / Completed
CompletedNCT00069862
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferitrin (GT56-252) | |
| DRUG | desferoxamine (DFO) |
Timeline
- Start date
- 2003-09-01
- Completion
- 2005-11-01
- First posted
- 2003-10-03
- Last updated
- 2015-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00069862. Inclusion in this directory is not an endorsement.